NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/05/2023
Back to search
Official data from USPTO
TMALIN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
16
Latest update
09/05/2023
Trademark type
Word
Nice classes
42
Filing date
04/14/2022
Registration date
09/05/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/05/2023
Last transaction
09/05/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
10/31/2022
First use in commerce
10/31/2022
Drawing code
4
Owner type
99
Owner location
Suzhou, Jiangsu, CN
Examiner
JAGANNATHAN, SIDDHARTH
Law office
M50
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
MediLink Therapeutics(Suzhou)Co.,Ltd.
Representatives
Timothy T. Wang NI, WANG & MASSAND, PLLC
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Biochemical research and development; Biomedical research services; Biotechnology research; Chemical research; Chemical research and analysis; Chemistry consultation; Development and test of chemical production methods; Development of pharmaceutical preparations and medicines; Medical and scientific researchconducting clinical trials for others; Pharmaceutical research and development; Professional consulting services and advice about agricultural chemistry; Providing medical and scientific research information in the field of clinical trials; Research and development in the field of antibody-drug conjugates; Research and development in the field of antibody conjugates; Research and development in the field of drug conjugates; Research and development in the pharmaceutical and biotechnology fields; Research and development services in the field of antibodies; Research in the field of chemistry; Scientific research for medical purposes in the area of cancerous diseases; Scientific research in the nature of conducting clinical trials for others; Technology research in the field of pharmaceutical preparations and medical instruments; Testing of chemicals; Testing of cosmetics; Testing of pharmaceuticals
Publications
History of USPTO decisions and trademark events.
16 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
09/05/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
08/04/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
08/03/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
08/03/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
08/03/2023
IUAF
USE AMENDMENT FILED
07/18/2023
EISU
TEAS STATEMENT OF USE RECEIVED
07/18/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
05/02/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/07/2023
PUBO
PUBLISHED FOR OPPOSITION
03/07/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/15/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/01/2023
DOCK
ASSIGNED TO EXAMINER
02/01/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/20/2022
NWAP
NEW APPLICATION ENTERED
04/18/2022
Continuous trademark protection
Get notified about every new filing that threatens TMALIN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.